The administration of iron aims to improve anemia, but it also appears to contribute to increase ferritin, as well as hepcidin levels, that may lead to worsening of functional iron deficiency, and, eventually, to hyporesponse to ESA therapy. The gene discussed is HAMP; the disease is anemia (phenotype).